Editorial


Emmanuel J. Favaloro, PhD, FFSc (RCPA)¹

¹ Department of Haematology, Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia


Welcome to the start of another year with Seminars in Thrombosis and Hemostasis (STH), this being my 12th year anniversary as Editor-in-Chief. As always, I wish to again sincerely thank all contributors to STH over the years, as well as guest editors for past issues, and of course the current and past editorial team. There has been no major overhaul of the editorial team at the time of writing, although some adjustments have and will continue to occur over coming years.

I also take this opportunity to once again thank the journal production team at Thieme Medical Publishers for their high production standards and for facilitating both the print and online issues of the journal. In particular, I would like to thank Ananya Das, the production editor for STH, and her production team, as well as Wakiko Ishii, an assistant acquisitions editor, for their ongoing support.

This now annual editorial also represents the time that we reflect on our journal’s Impact Factor, which for 2018 was 3.401, which represents a small increase from our 2017 Impact Factor of 3.345. I also assessed the trends for self-citations, and this reflects positively for recent data (Fig. 1). Finally, I also

[Figure 1: Percentage of self-citations for Seminars in Thrombosis and Hemostasis in recent years—aiming for less.]

Address for correspondence
Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales 2145, Australia (e-mail: emmanuel.favaloro@health.nsw.gov.au).

Issue Theme Perioperative Hemostasis; Guest Editors: Beverley J. Hunt, FRCP, FRCPath, MD, and Jerrold H. Levy, MD, FAHA, FCCM.

Copyright © 2020 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.


ISSN 0094-6176.
assessed how STH compared with several “comparable” journals focused on bleeding and/or thrombosis, and of 10 such journals, about half showed an increase, while the remainder showed a reduction or no change, in Impact Factor. In any case, the Impact Factor is only one of several markers of journal “quality” that we should consider, and the limitations of any individual marker (including the Impact Factor) as a “quality” indicator have previously been discussed.1,2

As I also do annually now, the highest cited (2016/2017-published) contributions3–38 from this journal are also listed in Table 1 for the potential interest of the readership and contributing authors. These contributions identify those publications most contributing to the 2018 Impact Factor, and each were cited six or more times in the literature in 2018. For those interested, the current listing can be compared with those of the most recently published top downloaded article listings from STH, the basis of the Eberhard F. Mammen “Most Popular” awards.39–42 Accordingly, I would like to thank all the contributors, guest editors, and the editorial team for bringing us the content that makes STH.

Table 1: Top 2018-cited papers, as published in 2016/2017

<table>
<thead>
<tr>
<th>No.</th>
<th>Authors</th>
<th>Title</th>
<th>Journal</th>
<th>Volume</th>
<th>Issue</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Gremmel T, Frelinger AL III, Michelson AD</td>
<td>Platelet physiology</td>
<td>Semin Thromb Hemost</td>
<td>2016;42(3)</td>
<td>191–204</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Berntorp E, Andersson NG</td>
<td>Prophylaxis for hemophilia in the era of extended half-life factor VIII/factor IX products</td>
<td>Semin Thromb Hemost</td>
<td>2016;42(5)</td>
<td>518–525</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Flevaris P, Vaughan D</td>
<td>The role of plasminogen activator inhibitor type-1 in fibrosis</td>
<td>Semin Thromb Hemost</td>
<td>2017;43(2)</td>
<td>169–177</td>
<td></td>
</tr>
<tr>
<td>10.</td>
<td>Schroeder V, Kohler HP</td>
<td>Factor XIII: structure and function</td>
<td>Semin Thromb Hemost</td>
<td>2016;42(4)</td>
<td>422–428</td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td>Litvinov RI, Weisel JW</td>
<td>What is the biological and clinical relevance of fibrin?</td>
<td>Semin Thromb Hemost</td>
<td>2016;42(4)</td>
<td>333–343</td>
<td></td>
</tr>
<tr>
<td>18.</td>
<td>Undas A</td>
<td>How to assess fibrinogen levels and fibrin clot properties in clinical practice?</td>
<td>Semin Thromb Hemost</td>
<td>2016;42(4)</td>
<td>381–388</td>
<td></td>
</tr>
</tbody>
</table>
Moreover, I am grateful that the journal made our article freely available following the 2018 Eberhard F. Mammen Award, which has certainly fostered its further distribution. Finally, I would like to thank all colleagues for their continued interest in our review article. Since Seminars in Thrombosis and Hemostasis publishes so many excellent papers, it is indeed a great honour that our article was the most highly cited within the last year.

Several issues of the journal are also worthy of highlighting as most contributing to the 2018 Impact Factor. The five most highly contributing issues,\textsuperscript{43–47} both in terms of total and average Impact Factor contributions, were as follows:


5. Laboratory Assessment of Hemostatic and Anticoagulant Therapy. Guest Editors: Dorothy M. Adcock, Robert C. Gosselin.

Finally, a short note to confirm that we, as always, will continue to develop plans for the future content of this journal, and we are confident that STH will be able to...
continue to bring its readers the high-quality journal that is expected of us. Currently confirmed topics for issues that we plan to publish over the next 12 or so months are listed in Table 2. At the same time, we recognize the need to retain some flexibility in our plans, and to potentially add additional material of current interest and controversy as the need arises. We look forward to another interesting year of reading in 2020.

Conflicts of Interest
None declared.

References
13 Litvinov RI, Weisel JW. What is the biological and clinical relevance of fibrin? Semin Thromb Hemost 2016;42(04):333–343
20 Undas A. How to assess fibrinogen levels and fibrin clot properties in clinical practice? Semin Thromb Hemost 2016;42(04):381–388
32 Lordkipanidzê M. Platelet function tests. Semin Thromb Hemost 2016;42(03):258–267
35 Just S. Laboratory testing for von Willebrand disease: the past, present, and future state of play for von Willebrand factor assays that measure platelet binding activity, with or without ristocetin. Semin Thromb Hemost 2017;43(01):75–91
36 Foley JH. Plasmin(ogen) at the nexus of fibrinolysis, inflammation, and complement. Semin Thromb Hemost 2017;43(02):135–142
42 Favaloro EJ. 2018 Eberhard F. Mammen Award announcements: Part II-Young investigator awards. Semin Thromb Hemost 2019;45(02):123–129
44 Hvas AM. Platelet function in thrombosis and hemostasis. Semin Thromb Hemost 2016;42(03):183–184